Goldenseal
StarHydrastis canadensis
Synonyms: Warneria canadensis, Warneria tinctoria, Hydrastis trifolia, Warneria diphylla
Western Herbalism Properties
Traditional Uses
Goldenseal was an important medicine for several eastern tribes. The Iroquois and Cherokee used the yellow rhizome and root extensively as a bitter stomach and digestive tonic and stimulant, and to treat skin disorders, diarrhoea, fevers, sore eyes and ears, liver and heart complaints, pulmonary trouble and tuberculosis, whooping cough and even cancer, and as an emetic; the Cherokee and others also used the rhizome as a yellow dye (Herrick/Iroquois; Hamel & Chiltoskey, 1975). It was adopted from Native American practice into mainstream nineteenth-century Eclectic medicine as a celebrated mucous-membrane tonic.
Gallery
Botanical Description
Hydrastis canadensis, goldenseal, is a low perennial herb of the buttercup family (Ranunculaceae) native to the rich, shady deciduous woodlands of eastern North America. It grows from a thick, knotty, bright yellow rhizome bearing numerous slender roots, the colour reflecting its content of the alkaloids berberine and hydrastine. Each plant typically produces a single hairy stem that forks near the top into two palmately lobed, sharply toothed, maple-like leaves; a single small, petalless flower with conspicuous greenish-white stamens is borne at the fork in spring. The flower is followed by a single raspberry-like cluster of inedible red berries. Once abundant, goldenseal has been heavily over-harvested from the wild for the herbal-medicine trade and is now a conservation concern, listed under CITES and considered threatened or vulnerable across much of its range; most ethical supply now comes from cultivation. It favours moist, humus-rich, well-drained forest soils under a hardwood canopy.
Active Constituents
Berberine
Isoquinoline (protoberberine) alkaloidConcentration: Major rhizome alkaloid, roughly 2-4.5% of dried root/rhizome
The bright-yellow quaternary alkaloid responsible for much of goldenseal's antimicrobial, antidiarrhoeal and metabolic activity; inhibits bacterial adhesion and has documented glucose- and lipid-lowering effects. Also a P-glycoprotein substrate/inhibitor.
Hydrastine
Phthalideisoquinoline alkaloidConcentration: Major rhizome alkaloid, roughly 2-4%
A characteristic goldenseal alkaloid with vasoconstrictive and astringent properties historically used for mucosal and uterine bleeding; a potent inhibitor of CYP3A4 (more so than berberine) underlying goldenseal's herb-drug interaction potential.
Canadine (tetrahydroberberine)
Isoquinoline alkaloidConcentration: Minor rhizome alkaloid
A reduced protoberberine alkaloid contributing to the alkaloid profile and antimicrobial/sedative activity of the root.
Berberastine
Isoquinoline alkaloidConcentration: Minor rhizome alkaloid
A hydroxylated berberine analogue found characteristically in Hydrastis, used alongside berberine and hydrastine as a chemical marker for authentication.
Canadaline
Seco-isoquinoline alkaloidConcentration: Minor constituent
A minor alkaloid contributing to the overall alkaloid fingerprint of goldenseal root.
Flavonoids (e.g. sideroxylin, 8-desmethyl-sideroxylin)
Methylated flavonesConcentration: Minor constituents of aerial parts and root
Flavonoids identified in goldenseal that show synergistic potentiation of berberine antibacterial activity by inhibiting bacterial multidrug-resistance efflux pumps.
⚠ Drug Interactions
CYP3A4 substrates (e.g. midazolam, cyclosporine, indinavir, some statins)
Goldenseal, chiefly via hydrastine and berberine, inhibits CYP3A4/5. In a controlled human study goldenseal reduced clearance of the CYP3A probe midazolam by roughly 40%, indicating clinically meaningful enzyme inhibition.
Clinical note: Avoid goldenseal with narrow-therapeutic-index CYP3A substrates; monitor for enhanced drug effect or toxicity.
CYP2D6 substrates (e.g. metoprolol, dextromethorphan, many antidepressants)
Human phenotyping studies show goldenseal significantly inhibits CYP2D6 activity, potentially raising levels of drugs cleared by this enzyme.
Clinical note: Use caution and monitor for exaggerated effects of CYP2D6 substrates when combined with goldenseal.
P-glycoprotein substrates (e.g. digoxin)
Berberine and goldenseal extracts modulate intestinal P-glycoprotein; pharmacokinetic modelling predicts changes in exposure to P-gp substrates such as digoxin.
Clinical note: Monitor for altered response to digoxin and other P-gp substrates.
Antidiabetic drugs
Berberine has well-documented glucose- and lipid-lowering activity, so combined use with antidiabetic agents may additively lower blood glucose.
Clinical note: Monitor blood glucose and adjust antidiabetic dosing as needed.
Preparation Methods
Tincture / hydroalcoholic extract
Parts: rhizome, root
Alcohol-water extract of the dried rhizome and root used as a bitter antimicrobial and mucous-membrane tonic. Because of potent CYP3A/2D6 inhibition, avoid with prescription medicines without professional advice.
Powdered root capsule
Parts: rhizome, root
Dried powdered rhizome in capsules, often standardized to hydrastine/berberine. Not for long-term or high-dose use.
Decoction / topical wash
Parts: rhizome, root
Root decoction historically used as an eyewash and mucosal wash. Safety warning: contraindicated in pregnancy and lactation (berberine is a uterine stimulant and can displace bilirubin, risking kernicterus in neonates); avoid in newborns. Goldenseal is listed on CITES Appendix II and is an at-risk species due to wild overharvest, so use only cultivated or sustainably sourced material.
Clinical Studies
Supplementation With Goldenseal (Hydrastis canadensis), but not Kava Kava (Piper methysticum), Inhibits Human CYP3A Activity In Vivo
In healthy volunteers, 14 days of goldenseal supplementation significantly reduced clearance of the CYP3A probe midazolam (about 40% inhibition), providing direct clinical evidence that goldenseal inhibits human CYP3A.
In Vivo Effects of Goldenseal, Kava Kava, Black Cohosh, and Valerian on Human Cytochrome P450 1A2, 2D6, 2E1, and 3A4/5 Phenotypes
Goldenseal supplementation for 28 days produced marked inhibition (about 40%) of both CYP2D6 and CYP3A4/5 activity in healthy volunteers, identifying it as one of the most potent botanical CYP inhibitors tested.
Physiologically based pharmacokinetic model predictions of natural product-drug interactions between goldenseal, berberine, imatinib and bosutinib
PBPK models integrating in vitro and clinical data quantified goldenseal- and berberine-mediated inhibition of CYP3A and P-glycoprotein, predicting the magnitude of interactions with substrate drugs.
Historical Texts
Cherokee and Iroquois ethnobotany (Native American traditional use)
Pre-Columbian and colonial eraKing's American Dispensatory (Felter and Lloyd)
19th century (Eclectic medicine, 1898 edition)References
- Mandal SK, Maji AK, Mishra SK, Ishfaq PM, Devkota HP, Silva AS, Das N. Goldenseal (Hydrastis canadensis L.) and its active constituents: A critical review of their efficacy and toxicological issues . Pharmacological Research (2020) [DOI]
- Gurley BJ, Swain A, Hubbard MA, Williams DK, Barone G, Hartsfield F, et al.. Supplementation with goldenseal, but not kava kava, inhibits human CYP3A activity in vivo . Clinical Pharmacology & Therapeutics (2008) [DOI]
This information is for educational purposes only and is not intended to replace professional medical advice. Always consult a qualified healthcare provider before using any herbal remedy, especially if you are pregnant, nursing, or taking medications.
📝 Notes
Public notes from the community and your own private notes on Goldenseal.
No notes yet.